News stories about ARMO BioSciences (NASDAQ:ARMO) have trended somewhat positive recently, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ARMO BioSciences earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.7834657236416 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
A number of research analysts have recently weighed in on ARMO shares. Robert W. Baird started coverage on shares of ARMO BioSciences in a research note on Tuesday, February 20th. They set an “outperform” rating and a $67.00 price objective for the company. Jefferies Group started coverage on shares of ARMO BioSciences in a research note on Tuesday, February 20th. They set a “buy” rating and a $61.00 price objective for the company. Leerink Swann raised shares of ARMO BioSciences from a “market perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research note on Tuesday, March 27th. Finally, BMO Capital Markets initiated coverage on shares of ARMO BioSciences in a research note on Tuesday, February 20th. They set an “outperform” rating and a $75.00 price objective for the company.
NASDAQ ARMO traded down $4.03 during mid-day trading on Friday, reaching $35.89. 232,790 shares of the stock were exchanged, compared to its average volume of 213,505. ARMO BioSciences has a 1-year low of $27.00 and a 1-year high of $57.19. The firm has a market cap of $1,091.24 and a P/E ratio of -1.26.
ARMO BioSciences (NASDAQ:ARMO) last announced its earnings results on Monday, April 2nd. The company reported ($9.62) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($9.17). analysts anticipate that ARMO BioSciences will post -2.34 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/armo-biosciences-armo-receives-daily-media-impact-rating-of-0-14.html.
About ARMO BioSciences
ARMO Biosciences, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company’s platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients.
Receive News & Ratings for ARMO BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARMO BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.